Fig. 1From: Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1Consolidated standards of reporting trials (CONSORT) flowchart. *Does not include the on-treatment deaths until 28 days of follow-upBack to article page